In addition, strategies targeting tumour antigens, namely vaccines, oncolytic viruses, and CAR-T-cells (Chimeric Antigen Receptor T-cells) may exploit differences in the clock and clock-controlled genes between GBM and healthy cells63,64. The gene discussed is CLOCK; the disease is glioblastoma.